Review Article
Cyclin-Dependent Kinase 5/p35/p39: A Novel and Imminent Therapeutic Target for Diabetes Mellitus
Table 1
IC50 (nM/μM) of various CDK5 inhibitors.
| Compound no. | Compound | Chemical name | IC50 CDK5/p25 |
| 1 | | 2-[[9-Methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-ethanol | 3 μM |
| 2 | | 2-(6-Benzylamino)-9-isopropyl-9H-purin-2-ylamino)butane-1-ol | 0.2 μM |
| 3 | | N-(5-(6,7-Diphenyl-5H-[]triazolo[3,4-b][]thiadiazin-3-yl)-4-methylthiophen-2-yl)acetamide | 44 ± 2 nM |
| 4 | | 2,2-Dichloro-N-(5-(6,7-Diphenyl-5H-[]triazolo[3,4-b][]thiadiazin-3-yl)-4-methylthiophen-2-yl) acetamide | 72 ± 2 nM |
| 5 | | N-(4-Methyl-5-(6-phenyl-[]triazolo[3,4-b][]thiadiazol-3-yl)thiophen-2-yl)acetamide | 42 ± 1 nM |
| 6 | | 2,2-Dichloro-N-(4-methyl-5-(6-phenyl-[]triazolo[3,4-b][]thiadiazol-3-yl)thiophen-2-yl)acetamide | 30 ± 1 nM |
| 7 | | 2-(4-(Benzylamino)-1-isopropyl-1H-benzo[d]imidazol-6-yloxy)butan-1-ol | 13 μM |
| 8 | | N-(3-((2-Acetamidothiazol-4-yl)methyl)-5-(2-(2-benzylidenehydrazinyl)-2-oxoethylthio)-4H-1,2,4-triazol-4-yl)benzamide | 048 ± 02 nM |
| 9 | | 1-((1H-Imidazol-5-yl)methyl)-7-fluoro-9H-pyrido[3,4-]indole | 05 μM |
| 10 | | | 34 ± 1 nM |
|
|